Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3
Patent Information
- Authority / Receiving Office
- US · United States
- Current Assignee / Owner
- VALNEVA SE
- Publication Date
- 2021-10-21
Smart Images
Figure 1 
Figure 2 
Figure 3
Abstract
Description
FIELD OF THE INVENTION
[0001] The invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same.BACKGROUND OF THE INVENTION
[0002] Chikungunya virus (CHIKV) is a positive-sense, single-stranded RNA virus from the genus Alphavirus, family Togaviridae. Chikungunya virus disease is mainly an outbreak disease and is associated with high attack rates. The virus is transmitted to humans via a mosquito vector and causes fever, rash, fatigue and severe polyarthralgia. Infections with CHIKV generally resolve spontaneously and are not usually fatal, except in rare cases involving CNS infection, where the death rate is between 10 to 30 percent. Particularly at risk for CHIKV CNS disease are infants under one year and adults over 65 years, with an infection rate 25-fold and 6-fold higher than the general population, respectively. The rate of persistent disabilities in children following CHIKV encephalitis is...